PREVENT was conducted at 220 sites in the US, Europe, Latin America, and Asia Pacific. The study randomized 3700 patients hospitalized for medical illnesses to receive either 5000 IU of subcutaneous ...
Thromboembol in blood vessel. Clot formation, 3D illustration Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback